Becton, Dickinson and Company (NYSE:BDX) Price Target Cut to $180.00 by Analysts at Argus

Becton, Dickinson and Company (NYSE:BDX) had its price objective decreased by Argus from $230.00 to $180.00 in a research note issued to investors on Monday morning,Benzinga reports. Argus currently has a buy rating on the medical instruments supplier’s stock.

BDX has been the topic of a number of other reports. TD Cowen lifted their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. dropped their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Bank of America lifted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Piper Sandler reiterated a “neutral” rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $191.62.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $156.01 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a 50 day moving average price of $184.60 and a 200-day moving average price of $188.57. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The stock has a market capitalization of $44.42 billion, a PE ratio of 25.45, a PEG ratio of 11.17 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has approved a share repurchase plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insider Activity

In related news, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 2,787 shares of company stock valued at $551,391. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 71.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares during the period. Transcend Capital Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares during the last quarter. Belpointe Asset Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter worth $650,000. Finally, Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 0.5% in the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after acquiring an additional 147,041 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.